

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 11, 2025

Transformation-related protein 63 (p63)

RRID:AB_2335989

Type: Antibody

Proper Citation

(Ventana Medical Systems Cat# 790-4509, RRID:AB_2335989)

Antibody Information

URL: http://antibodyregistry.org/AB_2335989

Proper Citation: (Ventana Medical Systems Cat# 790-4509, RRID:AB_2335989)

Target Antigen: ND

Host Organism: mouse

Clonality: monoclonal

Comments: Used By NYUIHC-915

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Transformation-related protein 63 (p63)

Description: This monoclonal targets ND

Clone ID: [4A4]

Antibody ID: AB_2335989

Vendor: Ventana Medical Systems

Catalog Number: 790-4509

Record Creation Time: 20231110T041942+0000

Record Last Update: 20241115T050819+0000

Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development
<https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Transformation-related protein 63 (p63).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. Cell reports. Medicine, 5(2), 101388.

Ishikawa T, et al. (2023) Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials. iScience, 26(5), 106695.

Millen R, et al. (2023) Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Med (New York, N.Y.), 4(5), 290.

Tata PR, et al. (2018) Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. Developmental cell, 44(6), 679.